Chinese guideline for diagnosis and treatment of adult acute lymphoblastic leukemia (2024)

VernacularTitle:中国成人急性淋巴细胞白血病诊断与治疗指南（2024年版）
Keywords: Leukemia, lymphoblastic, acute; Adult; Diagnosis; Treatment; Efficacy monitoring
From: Chinese Journal of Hematology 2024;45(5):417-429
CountryChina
Language:Chinese
Abstract: Adult acute lymphoblastic leukemia (ALL) is one of the most common acute leukemia in adults. There are relatively unified diagnostic criteria and systematic treatment regimens reported by different research groups in the world. Since 2013, three versions of expert consensus/guidelines on the diagnosis and treatment of adult ALL in China have been published, which are of great significance for improving the level of diagnosis and treatment of this disease. In 2022, the classification of ALL (precursor lymphocyte neoplasms-lymphoblastic leukemias/lymphomas) had been updated in the WHO classification of haematolymphoid tumors, and some new concepts had been proposed. In recent years, the rapid development of immunotherapy has improved the efficacy of adult ALL, and commercial antibodies and CAR-T cell products have been available in China, the clinical practice is increasing. In order to promote the standardization of clinical diagnosis and treatment of adult ALL, by referring to the latest guidelines and literatures all over the world, this guideline may contribute to the better understanding of diagnosis, treatment and efficacy monitoring for adult ALL.